FOSUN PHARMA (02196) News

Goldman Sachs and CLSA are concurrently bullish on China's innovative drugs! The underlying index of the Tianhong Innovative Drug ETF (517380) surged 3%, while the Tianhong Biomedical ETF (159859) has attracted over RMB 200 million in inflows for 12 consecutive days.

Gelonghui, September 14 | Today, CRO concept stocks in the A-share market rallied across the board. Among them, Kailain and Noah Health surged 9%, while YK Bio rose more than 4%, driving the

Gelonghui FinanceSep 14 13:00

Chinese Drug Regulator Accepts Fosun Pharma's Application for HLX14; Shares Up 5%

China's National Medical Products Administration accepted Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) application for the 120 milligram per vial of HLX14, or recombinant anti-RANKL fully

MT NewswiresSep 14 12:43

September 11 Buyback Roundup | Tencent, Baidu Group-W, and others conduct share buybacks, with Tencent spending HK$100 million

According to documents disclosed by the Hong Kong Exchange on September 14,$Tencent (00700.HK)$、$Baidu Group-W(09888.HK)$Pending share repurchase.① $Tencent (00700.HK)$On September 11, the company

Futu NewsSep 14 09:40

Goldman Sachs: Clear Recovery in China’s CRO/CDMO Sector; Bullish on WuXi AppTec, Pharmaron, Asymchem, Tigermed, and GenScript

Goldman Sachs released a research report stating that results for the second quarter and first half of the year indicate a clear recovery in China’s CRO/CDMO industry, with corporate earnings exceeding expectations, raised guidance, and strong order books. The firm assigned “Buy” ratings to Wuxi Apptec (02359.HK), Wuxi XDC (02268.HK), Asymchem (06821.HK), and Pharmaron (03759.HK), while assigning a “Neutral” rating to Wuxi Bio (02269.HK). Goldman Sachs covered Wuxi Apptec, Wuxi XDC, Wuxi Bio, Pharmaron, Asymchem, Tigermed (03347.HK), and GenScript (0

AASTOCKSSep 11 17:49

Fosun Pharma (600196.SH) subsidiary's registration application for HLX14, a biosimilar of denosumab, has been accepted.

Fosun Pharma (600196.SH) announced that its wholly owned subsidiary, Shanghai Henlius Biotech Co., Ltd., together with its controlled subsidiaries, has had its marketing authorization application

Zhitong FinanceSep 11 17:44

Fosun Pharma (02196.HK) repurchased 1.34 million shares on September 11 at a cost of HK$21.8642 million.

Gelonghui, September 11 — Fosun Pharma (02196.HK) announced that on September 11, 2026, it repurchased 1.34 million shares at a total cost of HK$21.8642 million, at prices ranging from HK$16.14 to HK$

Gelonghui FinanceSep 11 17:36

September 10 Buyback Roundup | Tencent and 3SBio, among others, conducted share buybacks, with Tencent spending HK$100 million

According to disclosure documents released by the Hong Kong Exchange on September 11, $Tencent(00700.HK)$ and $3SBio(01530.HK)$ repurchased shares. ① On September 10, $Tencent(00700.HK)$ repurchased 235,000 ordinary shares, involving an amount of HK$100 million, with the repurchase price per share ranging from HK$425.2 to HK$430.2. Since the resolution on the buyback mandate was passed, the cumulative number of securities repurchased stands at 44.8487 million shares, representing 0.49187% of the number of issued shares at the time the ordinary resolution was passed. ② $3SBio(01530.

Futu NewsSep 11 09:40

AI-driven drug development officially enters clinical validation phase, ushering in a golden era of growth for the industry chain

1. Insilico Medicine announced that its AI-driven innovative drug candidate, Rentosertib, has completed the enrollment and dosing of the first patient in the Phase III clinical trial GENESIS-IPF-3 for idiopathic pulmonary fibrosis. 2. China Merchants Securities noted that AI-driven drug discovery has completed proof of concept and officially entered the clinical validation stage, with initial signs of a commercialization inflection point emerging.

cls.cnSep 11 07:51

September 9 Buyback Roundup | Tencent, HSBC Holdings, and others conduct share buybacks, with Tencent spending HK$100 million

According to disclosure documents filed with the Hong Kong Exchange on September 10, companies including $Tencent (00700.HK)$ and $HSBC Holdings (00005.HK)$ repurchased shares. ① $Tencent (00700.HK)$ repurchased 231,000 ordinary shares on September 9, involving a total amount of HK$100 million, with repurchase prices ranging from HK$438.2 to HK$432.8 per share. Since the resolution authorizing share repurchases was passed, the cumulative number of securities repurchased stands at 44.6137 million shares, representing 0.48929% of the issued shares outstanding at the time the ordinary resolution was approved. ② $HSBC Holdings (00005.HK)$

Futu NewsSep 10 09:20

On September 9, Fosun Pharma (02196.HK) repurchased 152,500 shares at a total cost of HK$2.6298 million.

Gelonghui, September 9 | Fosun Pharma (02196.HK) announced that on September 9, 2026, it repurchased 152,500 shares at a total cost of HK$2.6298 million, with the repurchase price ranging from HK$17.16 to HK$17.26 per share.

Gelonghui FinanceSep 9 18:04

Sinopharm Group Stock Slips 2.1% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Sinopharm Group Co. Ltd. slid 2.1% to 15.70 Hong Kong dollars on what proved to be an all-

Dow JonesSep 9 16:32

Mainland China's 2026 National Reimbursement Drug List is expected to be released in November.

According to CCTV, the National Healthcare Security Administration organized on-site price negotiations for the 2026 National Reimbursement Drug List (NRDL) from September 5 to 8. Over 100 domestic and foreign enterprises participated in person, with 124 drugs not currently on the list shortlisted for negotiation. Innovative medicines in key areas of public concern, including oncology, rare diseases, chronic conditions, and pediatric treatments, were included in the negotiations and are expected to be added to the reimbursement list. Concurrently, adjustments to the innovative drug catalog for commercial health insurance were carried out, with 12 drugs undergoing on-site price consultations. The 2026 National Reimbursement Drug List and the Commercial Insurance Innovative Drug Catalog are scheduled for release in November this year, taking effect on January 1, 2027.

AASTOCKSSep 9 14:19

Citi Sticks to Their Buy Rating for Shanghai Fosun Pharmaceutical (Group) Co (SFOSF)

TipRanksSep 9 08:25

Fosun Pharma (02196) subsidiary's drug receives clinical trial approval

Fosun Pharma (02196) announced that its controlled subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (hereinafter referred to as "Fosun Pharma Industry"), has received approval from the National Medical Products Administration to conduct Phase II/III adaptive seamless design clinical trials of FXS5626 tablets (former project code: AC-201; hereinafter referred to as "FXS5626") for the treatment of non-segmental vitiligo. Fosun Pharma Industry plans to carry out relevant clinical studies of this drug in China once conditions permit.

Zhitong FinanceSep 8 17:47

Sinopharm Group Stock Climbs 1.3% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Sinopharm Group Co. Ltd. advanced 1.3% to 16.03 Hong Kong dollars on what proved to be an all-

Dow JonesSep 8 16:33

Share Buyback Roundup on September 7 | Bilibili-W, Tencent, and others conducted buybacks, with Bilibili-W spending HKD 784 million.

According to disclosures filed with the Hong Kong Exchange on September 8, companies including Bilibili-W (09626.HK) and Tencent (00700.HK) repurchased shares. ① On September 4, Bilibili-W (09626.HK) repurchased 6.7955 million Class B shares (shares with different voting rights), involving a total amount of HKD 784 million, with a repurchase price per share ranging from HKD 115.38 to HKD 115.38. ② On September 7, Tencent (00700.HK) repurchased 228,000 ordinary shares, involving a total amount of HKD 100 million, with a repurchase price per share ranging from HKD 442.4 to HKD 4

Futu NewsSep 8 09:30

Sinopharm Group Stock Rallies 0.9% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Sinopharm Group Co. Ltd. inched 0.9% higher to 15.83 Hong Kong dollars on what proved to be

Dow JonesSep 7 16:33

Hong Kong Stocks in Focus | Fosun Pharma surges over 8%, plans H-share buyback of up to HK$1 billion

Gelonghui, September 7 – Fosun Pharma (2196.HK) surged more than 8% during trading to HK$17.55. On the news front, the company announced that, with the approval of the Board of Directors, it plans to repurchase H shares over a 12-month period starting from August 27 this year, with the total amount for the share repurchase not exceeding HK$1 billion. The Board of Directors is confident in the group’s business development and prospects, and believes that the current H-share price is below its intrinsic value. Accordingly, the Board believes that implementing the share repurchase plan is in the best interests of the company and its shareholders as a whole.

Gelonghui FinanceSep 7 14:49

Fosun Pharmaceutical Extends Deadline of 81 Million Yuan Shareholder Loans to Fuyun Health; Shares Up 7%

Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196), along with its controlling shareholder and subsidiaries, agreed to extend the shareholder loans worth 80.8 million yuan provided to Fuyun Health

MT NewswiresSep 7 13:05

Hong Kong Stock Market Movers | Fosun Pharma (02196) rises over 5% in early trading after controlling subsidiary sells approximately 6.00% stake in Gland Pharma for INR 27.996 billion

Fosun Pharma (02196) rose more than 5% in early trading. As of press time, the stock was up 4.63% at HK$16.95, with a turnover of HK$31.68 million.

Zhitong FinanceSep 7 09:35